LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/ERK (MAPK) pathway, predominantly KIAA1549:...

Source: BMC Cancer - January 30, 2024 Category: Cancer & Oncology Authors: Cornelis M. van Tilburg, Lindsay B. Kilburn, S ébastien Perreault, Rene Schmidt, Amedeo A. Azizi, Ofelia Cruz-Martínez, Michal Zápotocký, Katrin Scheinemann, Antoinette Y. N. Schouten-van Meeteren, Astrid Sehested, Enrico Opocher, Pablo Hernáiz Driev Tags: Study Protocol Source Type: research